Skip to search formSkip to main contentSkip to account menu

temsirolimus

Known as: 42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin, 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin, temsirolimus [Chemical/Ingredient] 
An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs… 
National Institutes of Health

Related topics

Related topics

10 relations
1.2 ML temsirolimus 25 MG/ML Injection [Torisel]FRAP1 protein, humanNCIt Antineoplastic Agent TerminologyNegative Regulation of G1 Phase

Narrower (2)

CCI 779Torisel

Broader (1)

Sirolimus

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The use of prognostic factors in metastatic renal cell carcinoma.
2014
2014
Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors
The combination of vinblastine and mammalian target of rapamycin (mTOR) inhibitor sirolimus inhibits the growth of neuroblastoma… 
2013
2013
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Highly Cited
2012
Highly Cited
2012
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Review
2012
Review
2012
Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review.
Highly Cited
2011
Highly Cited
2011
A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas
The primary goal of this trial was to evaluate the confirmed response rate of temsirolimus (CCI‐779), a mammalian target of… 
Review
2010
Review
2010
Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
Metastatic renal cell carcinoma has harboured a poor prognosis for decades with immunotherapy being the only available therapy… 
2009
2009
18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model
To be a reliable predictor of response, tracer uptake should reflect changes in the amount of active tumor cells. However, uptake… 
Highly Cited
2007
Highly Cited
2007
Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma
Purpose: To characterize the pharmacokinetics of temsirolimus and its major metabolite, sirolimus, in patients receiving enzyme… 
Review
2007
Review
2007
Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)